Pharma BD Deal Intelligence

Johnson & Johnson / Cougar Biotechnology, Inc.

2009 · Acquisition/Merger · $970M · Complete

Announcement Sentiment

100

Strongly positive

$43/share tender; ~$894M equity + cash on hand = ~$970M. Acquired abiraterone (Zytiga) for prostate cancer. Closed Q3 2009. Source: J&J IR, SEC, Cravath, Fierce Biotech.

Key facts

Announced May 21, 2009
Deal value $970M
Deal type Acquisition/Merger

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals